A photo of Mariko DeWire.

Member, Division of Oncology

Associate Professor, UC Department of Pediatrics

513-517-2234

513-636-3549

Board Certified

My Biography & Research

Biography

Mariko D. DeWire-Schottmiller, MD, completed her graduate medical training at the Boonshoft School of Medicine at Wright State University, residency training in pediatrics at Lebonheur Children's Medical Center, and pediatric hematology/oncology training at St. Jude Children's Research Hospital in Memphis, Tennessee, with a focus on pediatric neuro-oncology.

Dr. DeWire-Schottmiller's clinical and academic interests pertain to children and families affected by central nervous system tumors. She is a member of the Central Nervous System (Brain Tumor) Committee in the Children's Oncology Group (COG) as well as the Cincinnati Children's co-principal investigator for the Pediatric Brain Tumor Consortium (PBTC).

Academic Affiliation

Associate Professor, UC Department of Pediatrics

Divisions

Cancer and Blood Diseases, Brain Tumor, Cancer and Blood Diseases



Blog Posts

We Need to Do Better for Patients Like Lauren Hill

BlogCancer and Blood Diseases

We Need to Do Better for Patients Like Lauren Hill

By Mariko DeWire, MD10/29/2014

My Locations

My Education

MD: Boonshoft School of Medicine at Wright State University, Dayton, OH.

Residency: Pediatrics, University of Tennessee College of Medicine.

Fellowship: Pediatric Hematology/Oncology, University of Tennessee College of Medicine and St. Jude Children’s Research Hospital.

My Publications

Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas. Salloum, R; McConechy, MK; Mikael, LG; Fuller, C; Drissi, R; DeWire, M; Nikbakht, H; De Jay, N; Yang, X; Boue, D; et al. Acta Neuropathologica Communications. 2017; 5.

BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma. Kumar, SS; Sengupta, S; Lee, K; Hura, N; Fuller, C; DeWire, M; Stevenson, CB; Fouladi, M; Drissi, R. Oncotarget. 2017; 8:62962-62975.

The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas. Anderson, JL; Muraleedharan, R; Oatman, N; Klotter, A; Sengupta, S; Waclaw, RR; Wu, J; Drissi, R; Miles, L; Raabe, EH; et al. Neuro-Oncology. 2017; 19:1068-1078.

The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas. Anderson, JL; Muraleedharan, R; Oatman, N; Klotter, A; Sengupta, S; Waclaw, RR; Wu, J; Drissi, R; Miles, L; Raabe, EH; et al. Neuro-Oncology. 2017; 19:1068-1078.

Radiation and subsequent reirradiation outcomes in the treatment of diffuse intrinsic pontine glioma and a systematic review of the reirradiation literature. Freese, C; Takiar, V; Fouladi, M; DeWire, M; Breneman, J; Pater, L. Practical Radiation Oncology. 2017; 7:86-92.

A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas. Hummel, TR; Salloum, R; Drissi, R; Kumar, S; Sobo, M; Goldman, S; Pai, A; Leach, J; Lane, A; Pruitt, D; et al. Journal of Neuro-Oncology. 2016; 127:53-61.